Provided by Tiger Trade Technology Pte. Ltd.

Anika Therapeutics

21.43
-0.3500-1.61%
Volume:94.58K
Turnover:2.08M
Market Cap:286.80M
PE:-77.36
High:22.53
Open:22.53
Low:21.30
Close:21.78
52wk High:22.88
52wk Low:8.37
Shares:13.38M
Float Shares:11.29M
Volume Ratio:0.70
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2770
EPS(LYR):-0.7628
ROE:-2.19%
ROA:-0.87%
PB:2.09
PE(LYR):-28.09

Loading ...

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.d. to Its Board of Directors

THOMSON REUTERS
·
Apr 16

Anika Therapeutics to release first-quarter results, host conference call

Reuters
·
Apr 16

Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

GlobeNewswire
·
Apr 16

Anika Therapeutics grants 3,138 RSUs to new hire under inducement plan

Reuters
·
Apr 04

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 04

Switzerland's Medacta FY revenue rises, profit up on Parcus Medical acquisition

Reuters
·
Mar 13

Anika Therapeutics Earnings Call Signals Cautious Rebound

TIPRANKS
·
Mar 08

Anika Therapeutics Is Maintained at Outperform by Barrington Research

Dow Jones
·
Feb 28

B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating

MT Newswires Live
·
Feb 27

Anika FY 2025 GAAP loss from continuing operations hits USD 10.0 million

Reuters
·
Feb 26

Anika Therapeutics Q4 Adj. EPS $0.31 Beats $(0.21) Estimate, Sales $30.615M Beat $28.875M Estimate

Benzinga Earnings
·
Feb 26

BRIEF-Anika Therapeutics Q4 Revenue USD 30.615 Million

Reuters
·
Feb 26

Anika Therapeutics Q4 Net Income USD 292 Thousand

THOMSON REUTERS
·
Feb 26

Anika Therapeutics Outlook FY Revenue USD 114-122.5 Million

THOMSON REUTERS
·
Feb 26

Anika Therapeutics Inc: Cingal and Hyalofast Remain Core Strategic Priorities for 2026 as We Prepare for Future U.S. Market Launches

THOMSON REUTERS
·
Feb 26

Anika Therapeutics Inc: Reaffirms 2026 Revenue

THOMSON REUTERS
·
Feb 26

Anika Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Feb 26

Anika Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
Feb 24

Anika Therapeutics CEO Steve Griffin to Present at Canaccord Genuity 2026 Musculoskeletal Conference

Reuters
·
Feb 19

Anika Therapeutics Inc. to Announce Fourth Quarter and Year-End Financial Results

Reuters
·
Feb 13